The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksC4XD.L Share News (C4XD)

  • There is currently no data for C4XD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

C4X Discovery CEO to be interim chair of UK Vaccine Taskforce

Tue, 08th Dec 2020 12:26

(Sharecast News) - Drug discovery company C4X Discovery confirmed on Tuesday that its chief executive officer Clive Dix has stepped into the role of interim chair of the UK Vaccine Taskforce.
The taskforce is a group set up by the government to lead the country's efforts to find and manufacture a Covid-19 vaccine.

It would set out arrangements for the long-term leadership of the Vaccine Taskforce shortly.

The AIM-traded firm said Dix was delivering on the company's strategy to advance its portfolio, adding that the appointment would not impact his day-to-day role as CEO.

"The taskforce has worked tirelessly to seek and secure new vaccines for Covid-19," said C4X chairman Eva-Lotta Allan.

"This important work has resulted in the UK being at the forefront of both receiving and developing these critical vaccines and demonstrates the expertise and drive of all those involved.

"As Kate Bingham has reached the end of her agreed tenure as chair, to ensure the smooth continuity of the work carried out by the taskforce, Clive is stepping into the role as chair for an interim period."

Allan said Dix was delivering "strong" leadership at C4X, with a recent fundraise of £15m, which provided a "strong foundation" to continue driving focussed progress across its core portfolio.

"We look forward to providing a more in-depth update at our preliminary results later this month."

At 0845 GMT, shares in C4X Discovery Holdings were down 1.88% at 18.25p.
More News
7 May 2020 17:57

C4X Discovery Raises GBP1.6 Million Via Share Placing

C4X Discovery Raises GBP1.6 Million Via Share Placing

Read more
24 Jan 2020 15:59

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
7 Jan 2020 10:40

C4X Discovery Annual Loss Widens, Confident In Strategy

C4X Discovery Annual Loss Widens, Confident In Strategy

Read more
7 Jan 2020 09:59

C4X losses widen as its revenue drops to nil

(Sharecast News) - Drug discovery company C4X Discovery Holdings announced a fall in revenue to nil in its full-year results on Tuesday, from £7.06m in 2018, which the board said as driven entirely by the Indivior licensing agreement in that year.

Read more
31 Dec 2019 10:47

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
24 Oct 2019 17:06

UPDATE: C4X Discovery Raises GBP7 Million In Discounted Placing

UPDATE: C4X Discovery Raises GBP7 Million In Discounted Placing

Read more
24 Oct 2019 11:09

C4X Discovery Raises Over GBP5 Million In Discounted Placing

C4X Discovery Raises Over GBP5 Million In Discounted Placing

Read more
24 Oct 2019 10:31

UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped

UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped

Read more
1 Oct 2019 10:15

C4X makes solid progress across portfolio of programmes

(Sharecast News) - Drug discovery company C4X Discovery Holdings announced progress across a number of key programmes in line with its strategy on Tuesday, reporting that it was continuing to progress its strategy to deliver programmes for out-licensing its NRF-2 activator, IL-17 inhibitor and LifeArc collaboration.

Read more
27 Sep 2019 15:39

C4X upbeat as its molecule progresses with Indivior

(Sharecast News) - Drug discovery company C4X Discovery Holdings noted an announcement on Friday that the National Institutes of Health (NIH) in the United States has granted Indivior's application titled "Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder'.

Read more
2 Sep 2019 12:02

Former Glaxo Vice President To Lead C4X Discovery Advisory Network

(Alliance News) - C4X Discovery Holdings PLC on Monday said it is forming a drug discovery advisory network chaired by "renowned industry veteran" Robin Carr.Shares in C4X were up

Read more
30 Apr 2019 12:59

C4X Discovery Interim Loss Widens, Focuses On Inking Deals

LONDON (Alliance News) - C4X Discovery Holdings PLC said on Tuesday it had a "strong" first half, though its loss widened on higher research and development costs.The drug firm to

Read more
23 Apr 2019 16:03

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 24 April PetropavolskFull Year ResultsBoohoo GroupFull Year HealthFull

Read more
6 Dec 2018 16:04

E-Therapeutics and C4X upbeat on Parkinson's collaboration

(Sharecast News) - Network-driven drug discovery company e-Therapeutics and C4X Discovery Holdings updated the market on their collaboration on Thursday, to identify novel intervention strategies for the potential treatment of Parkinson's Disease (PD).

Read more
6 Dec 2018 09:23

e-Therapeutics And C4X Identify New Pathways For Parkinson's Treatment

LONDON (Alliance News) - C4X Discovery Holdings PLC and e-Therapeutics PLC on Thursday said that, through their collaboration, they discovered additional novel biological pathways for the of that

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.